Emtricitabine (Emtricitabine) Patent Expiration, LOE Window & CMS Spending

Emtricitabine (Emtricitabine) by Aurobindo Pharma: Multi-Source Generic Molecule, 2 AB generics, $2.3M 2024 CMS Part D & Medicaid spend, and $3,499 CA SB 17 specialty launch WAC.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorAurobindo Pharma
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors2
2024 CMS Total Public Spend$2.3M
2024 Medicare Part D Spend$1.9M
2024 Medicaid Spend$387K
Reported Wholesale Price Change (CA SB 17)Specialty launch notice ($3,499 intro WAC)